Agilent Technologies Inc

Análisis de la acción Agilent Technologies Inc (A)

$175.550

+1.562 (+0.89%)Al cierre

Loading chart…
Máximo
177.040
Apertura
175.000
Precio medio ponderado por volumen
175.43
Volumen
1.89M
Capitalización
38.16B
Mínimo
173.690
Importe
332.20M
EV/EBITDA, TTM
21.88

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

www.agilent.com

Análisis de IA of Agilent Technologies Inc (A)

Comprar

Agilent Technologies Inc is a good buy right now due to its strong financial performance and positive market outlook. The current price is $170.54, with a forward P/E ratio of 23.87, indicating reasonable valuation for growth. The gross margin has improved to 55.54%, reflecting operational efficiency. Additionally, analysts have set a price target range between $180 and $195, suggesting a potential upside of approximately 5.5% to 14.4%. The main risk is the recent decline in liquid chromatography-mass spectrometry equipment sales, which may affect future revenue growth.

Métricas de valoración

El PER previsto actual de Agilent Technologies Inc (A) es 23.87, frente a su media de 5 años de 23.99.

PER previsto

Valor razonable
Media 5A P/E
23.99
P/E actual
23.87
Sobrevalorada
27.06
Infravalorada
20.92

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
19.70
EV/EBITDA actual
21.88
Sobrevalorada
22.02
Infravalorada
17.37

Precio/ventas previsto

Valor razonable
Media 5A P/S
5.52
P/S actual
6.06
Sobrevalorada
6.23
Infravalorada
4.80

Escenarios de precio de Alphio AI para A

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%A

$115.77

Precio del escenario

B

Base

Base · 50%A

$100.17

Precio del escenario

B

Bajista

Bajista · 25%A

$81.51

Precio del escenario

Ballenas con A en cartera

C

CCLA Investment Management Limited

+ Con en carteraA

+7.80%

Rentabilidad a 3 meses

T

Troy Asset Management Ltd

+ Con en carteraA

+7.07%

Rentabilidad a 3 meses

H

Harvest Portfolios Group Inc.

+ Con en carteraA

+6.96%

Rentabilidad a 3 meses

C

Candriam, Société En Commandite Par Actions

+ Con en carteraA

+5.43%

Rentabilidad a 3 meses

L

LGT Capital Partners Ltd.

+ Con en carteraA

+5.38%

Rentabilidad a 3 meses

D

Deroy & Devereaux Private Investment Counsel, Inc.

+ Con en carteraA

+4.94%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-01 (ET)

08:30:00

Agilent Launches NovoStation Sample Preparation System

2026-09-29 (ET)

08:30:00

Agilent Launches Gen5 AI Cell Identification Module

2026-09-21 (ET)

08:31:00

Agilent Launches TapeStationDx Systems for Clinical Labs

2026-09-08 (ET)

08:30:00

Agilent Technologies Independent Chair Koh Boon Hwee Retires

Noticias

Preguntas frecuentes sobre A, respondidas por Alphio AI

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Agilent Technologies Inc is a good buy right now due to its strong financial performance and positive market outlook. The current price is $170.54, with a forward P/E ratio of 23.87, indicating reasonable valuation for growth. The gross margin has improved to 55.54%, reflecting operational efficiency. Additionally, analysts have set a price target range between $180 and $195, suggesting a potential upside of approximately 5.5% to 14.4%. The main risk is the recent decline in liquid chromatography-mass spectrometry equipment sales, which may affect future revenue growth.

Comunidad

Más ↗

$BinanceBee Liangxi has issued another token! It's getting more and more like a cash grab. Truly shameless. All the good reputation from before has been used to harvest retail investors.

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar